Miracle Leaf® qualifying-conditions guide

Medical Marijuana for Inflammatory Bowel Disease

Group of chronic inflammatory conditions of the gastrointestinal tract, including Crohn's disease and ulcerative colitis. Cannabis has limited evidence for symptomatic improvement but no evidence for inducing or maintaining clinical remission.

Reviewed by Miracle Leaf® Editorial Team

Last reviewed 2026-05-15

Book Evaluation Call (833) LEGAL-MJ

NASEM evidence levelLimitedICD-10: K51.90

What is Inflammatory Bowel Disease?

Inflammatory bowel disease (IBD) is the umbrella term for a group of chronic inflammatory conditions of the gastrointestinal tract, principally Crohn's disease and ulcerative colitis. Both produce abdominal pain, diarrhea, fatigue, weight loss, and extraintestinal complications. The conditions differ in inflammation pattern: Crohn's can affect any part of the GI tract in patchy distribution, while ulcerative colitis is restricted to the colon in continuous distribution.

Treatment ranges from aminosalicylates and corticosteroids in mild disease to biologic therapies (anti-TNF, anti-integrin, anti-interleukin) and surgery in moderate-to-severe cases.

Does cannabis help Inflammatory Bowel Disease?

The 2017 NASEM consensus report classified cannabis evidence for IBD as limited. Small randomized trials and patient-reported outcomes describe improvements in pain, quality of life, sleep, and appetite, but no trial has demonstrated cannabis or cannabinoids as effective for inducing or maintaining clinical remission as measured by endoscopic, biomarker, or histologic outcomes.

IBD (or Crohn's and ulcerative colitis separately) is a qualifying condition under most US state medical cannabis programs. Patients should not substitute cannabis for evidence-based IBD therapy and should coordinate use with their gastroenterology team.

Eligibility

State eligibility for Inflammatory Bowel Disease

Whether this condition is listed varies by state program. A Miracle Leaf® physician determines eligibility during your evaluation.

State-by-state eligibility for Inflammatory Bowel Disease: whether the condition qualifies under Florida, Georgia, and Texas medical cannabis programs.
State	Qualifies?	Program
Florida	Not listed	Florida OMMU
Georgia	Not listed	Georgia DPH Low-THC Registry
Texas	Not listed	Texas Compassionate Use Program

Outside Florida, Georgia, or Texas?

Telehealth visits are available in 22 states. See telehealth states

Common questions

Frequently asked questions

Does cannabis induce remission in inflammatory bowel disease?

No. Available trials show symptomatic improvement (pain, appetite, sleep) but no reduction in objective markers of intestinal inflammation and no induction of clinical remission. The 2017 NASEM report did not identify high-tier evidence for cannabis in IBD. Cannabis is not a substitute for disease-modifying therapy.

Is any cannabis-derived product FDA-approved for IBD?

No. No cannabis or cannabinoid product is FDA-approved for Crohn's disease, ulcerative colitis, or any inflammatory bowel disease. Standard treatment includes aminosalicylates, corticosteroids, immunomodulators, and biologic therapies (anti-TNF, anti-integrin, anti-interleukin).

What are the most common cannabis-use considerations for IBD patients?

Smoking and chronic cannabis use are associated with worse Crohn's outcomes; non-inhaled forms (oils, tinctures, edibles) are generally preferred. Cannabis interacts with immunosuppressants and biologics through hepatic metabolism. Patients should disclose use to their gastroenterologist and should not discontinue disease-modifying therapy in favor of cannabis.

Why do some state programs enumerate IBD separately from Crohn's disease?

State statutes vary in granularity. Some list "inflammatory bowel disease" as the inclusive category covering Crohn's and ulcerative colitis; others enumerate Crohn's specifically while excluding ulcerative colitis from the qualifying list. The duplicated coverage on mmjnow exists because both terms appear in different state statutes and patients may be looking for either.

Sources and citations

Ready to talk with a Miracle Leaf® physician?

Book Evaluation Call (833) LEGAL-MJ Shop Now

Reviewed by Miracle Leaf® Editorial Team. This page summarizes current peer-reviewed evidence and federal guidance and is updated when the source documents materially change.